Balanced information belongs beside every treatment option.

Compounded NAD+ is not FDA approved. FDA does not verify compounded drugs for safety, effectiveness, or quality before marketing.

Compounded products can carry risks related to strength, contamination, sterility, storage, and administration. Your clinician should explain why a compounded option is being considered.

FDA has reported adverse events after injectable NAD+ products, including severe chills, shaking, vomiting, and fatigue. Some people required medical treatment.

FDA has also warned about food grade NAD+ used in intravenous products. If an injectable route is considered, the pharmacy must document suitable ingredients, supplier controls, sterility, endotoxin testing, and release.

The final safety page will identify the exact route offered and include partner approved instructions for side effects and urgent concerns.

Read the FDA sterile compounding and NAD+ safety reminder

• Tell the clinician about all medications and supplements.
• Share allergies, reactions, conditions, and prior treatments.
• Ask about evidence, uncertainty, risks, and alternatives.
• Confirm the dispensing pharmacy and its contact information.
• Understand storage, administration, and follow up instructions.

Follow the final pharmacy and clinician instructions. Contact the care team promptly for concerning or unexpected symptoms.

Call 911 or go to the nearest emergency room for a medical emergency. This website does not provide emergency care.